Vistagen Therapeutics, Inc. Stock price

Equities

VTGN

US92840H4002

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:56:36 2024-03-28 am EDT 5-day change 1st Jan Change
4.665 USD +2.08% Intraday chart for Vistagen Therapeutics, Inc. +10.68% -9.24%
Sales 2024 * 1.06M Sales 2025 * 170K Capitalization 124M
Net income 2024 * -30M Net income 2025 * -61M EV / Sales 2024 * 8.86 x
Net cash position 2024 * 114M Net cash position 2025 * 60.6M EV / Sales 2025 * 371 x
P/E ratio 2024 *
-2.86 x
P/E ratio 2025 *
-2.33 x
Employees 37
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.06%
1 week+9.59%
Current month-10.57%
1 month-13.61%
3 months-11.09%
6 months-13.28%
Current year-11.09%
More quotes
1 week
4.12
Extreme 4.1162
4.65
1 month
3.91
Extreme 3.9114
5.31
Current year
3.91
Extreme 3.9114
5.86
1 year
1.62
Extreme 1.62
24.71
3 years
1.62
Extreme 1.62
106.50
5 years
1.62
Extreme 1.62
106.50
10 years
1.62
Extreme 1.62
495.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 99-12-31
Director of Finance/CFO 55 23-08-20
Chief Operating Officer 54 21-10-31
Members of the board TitleAgeSince
Chairman 88 00-05-31
Director/Board Member 81 16-02-29
Chief Executive Officer 61 99-12-31
More insiders
Date Price Change Volume
24-03-28 4.66 +1.97% 53 139
24-03-27 4.57 +5.06% 324,181
24-03-26 4.35 +1.64% 173,613
24-03-25 4.28 +2.64% 224,707
24-03-22 4.17 -1.07% 132,516

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. PH94B is a synthetic investigational pherine from the androstane family.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.57 USD
Average target price
13.25 USD
Spread / Average Target
+189.93%
Consensus
  1. Stock
  2. Equities
  3. Stock Vistagen Therapeutics, Inc. - Nasdaq